A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJiangsu HengRui Medicine Co., Ltd.
About this trial
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
Eligibility criteria
Qualifiers
Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;
Aged between 18-75 years old;
ECOG performance status (PS) score of 0 or 1;
Life expectancy > 3 months;
Disqualifiers
Toxicity from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion/exclusion criteria;
Presence of central nervous system (CNS) metastases;
Participants with gastrointestinal diseases that affect drug administration/absorption;
Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;
Trial design
Treatments tested in this trial
- HRS-7172 Tablets
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov